靶向衰老胆管细胞和活化成纤维细胞的B细胞淋巴瘤-特大抑制剂改善多药耐药2基因敲除(Mdr2-/-)小鼠的纤维化
在Mdr2-/-小鼠模型中,衰老胆管细胞通过血小板衍生生长因子依赖方式激活静息间充质细胞,Bcl-xL是PDGF活化的人和小鼠成纤维细胞及衰老胆管细胞的关键生存因子。使用Bcl-xL抑制剂A-1331852治疗Mdr2-/-小鼠可使衰老胆管细胞减少80%,减少促纤维化生长因子和细胞因子,减少α-平滑肌肌动蛋白阳性活化成纤维细胞,并显著减轻肝纤维化。
要点
- 衰老胆管细胞以PDGF依赖方式促进静息间充质细胞活化。
- Bcl-xL是PDGF活化成纤维细胞和衰老胆管细胞的关键生存因子。
- A-1331852治疗Mdr2-/-小鼠使衰老胆管细胞减少80%并显著减轻肝纤维化。
核心结论
- Bcl-xL是活化基质成纤维细胞和衰老胆管细胞的关键生存因子,使用Bcl-xL特异性抑制剂A-1331852可减轻肝纤维化,可能通过对活化成纤维细胞和衰老胆管细胞的双重作用实现,该机制是胆汁性纤维化有吸引力的治疗策略。
研究设计与样本
- 研究采用共培养系统、体外实验和多药耐药2基因敲除(Mdr2-/-)小鼠模型,评估Bcl-xL抑制对活化成纤维细胞和衰老胆管细胞的作用及对肝纤维化的影响。
主要发现
- 共培养系统中衰老胆管细胞以血小板衍生生长因子(PDGF)依赖方式促进静息间充质细胞活化。
- Bcl-xL是PDGF活化的人和小鼠成纤维细胞的关键生存因子,在衰老胆管细胞中也上调。
- 体外用小分子Bcl-2同源结构域3模拟物A-1331852或Bcl-xL特异性小干扰RNA抑制Bcl-xL,诱导PDGF活化成纤维细胞凋亡,但不诱导静息成纤维细胞凋亡。
- 抑制Bcl-xL降低衰老胆管细胞存活并增加其凋亡,与非衰老细胞相比。
- A-1331852治疗Mdr2-/-小鼠使衰老胆管细胞减少80%,减少促纤维化生长因子和细胞因子,减少α-平滑肌肌动蛋白阳性活化基质成纤维细胞,并显著减轻肝纤维化。
临床怎么用
- 原文结论认为该机制是胆汁性纤维化有吸引力的治疗策略,未给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Cholangiocyte senescence has been linked to primary sclerosing cholangitis (PSC). Persistent secretion of growth factors by senescent cholangiocytes leads to the activation of stromal fibroblasts (ASFs), which are drivers of fibrosis. The activated phenotype of ASFs is characterized by an increased sensitivity to apoptotic stimuli. Here, we examined the mechanisms of apoptotic priming in ASFs and explored a combined targeting strategy to deplete senescent cholangiocytes and ASFs from fibrotic tissue to ameliorate liver fibrosis. Using a coculture system, we determined that senescent cholangiocytes promoted quiescent mesenchymal cell activation in a platelet-derived growth factor (PDGF)-dependent manner. We also identified B-cell lymphoma-extra large (Bcl-xL) as a key survival factor in PDGF-activated human and mouse fibroblasts. Bcl-xL was also up-regulated in senescent cholangiocytes. In vitro, inhibition of Bcl-xL by the small molecule Bcl-2 homology domain 3 mimetic, A-1331852, or Bcl-xL-specific small interfering RNA induced apoptosis in PDGF-activated fibroblasts, but not in quiescent fibroblasts. Likewise, inhibition of Bcl-xL reduced the survival and increased apoptosis of senescent cholangiocytes, compared to nonsenescent cells. Treatment of multidrug resistance 2 gene knockout (Mdr2-/- ) mice with A-1331852 resulted in an 80% decrease in senescent cholangiocytes, a reduction of fibrosis-inducing growth factors and cytokines, decrease of α-smooth muscle actin-positive ASFs, and finally in a significant reduction of liver fibrosis. CONCLUSION: Bcl-xL is a key survival factor in ASFs as well as in senescent cholangiocytes. Treatment with the Bcl-xL-specific inhibitor, A-1331852, reduces liver fibrosis, possibly by a dual effect on activated fibroblasts and senescent cholangiocytes. This mechanism represents an attractive therapeutic strategy in biliary fibrosis. (Hepatology 2018;67:247-259).
引用
- Moncsek A, Al-Suraih MS, Trussoni CE, et al. Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2-/- ) mice. Hepatology. 2017. PMID: 28802066. doi:10.1002/hep.29464
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。